Cidara Therapeutics Net Income 2014-2022 | CDTX
Cidara Therapeutics net income from 2014 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Cidara Therapeutics Annual Net Income (Millions of US $) |
2021 |
$-42 |
2020 |
$-75 |
2019 |
$-41 |
2018 |
$-69 |
2017 |
$-56 |
2016 |
$-48 |
2015 |
$-32 |
2014 |
$-12 |
2013 |
$-1 |
Cidara Therapeutics Quarterly Net Income (Millions of US $) |
2022-03-31 |
$-18 |
2021-12-31 |
$-15 |
2021-09-30 |
$-18 |
2021-06-30 |
$9 |
2021-03-31 |
$-18 |
2020-12-31 |
$-22 |
2020-09-30 |
$-18 |
2020-06-30 |
$-18 |
2020-03-31 |
$-17 |
2019-12-31 |
$-14 |
2019-09-30 |
$3 |
2019-06-30 |
$-14 |
2019-03-31 |
$-17 |
2018-12-31 |
$-12 |
2018-09-30 |
$-14 |
2018-06-30 |
$-27 |
2018-03-31 |
$-17 |
2017-12-31 |
$-13 |
2017-09-30 |
$-12 |
2017-06-30 |
$-17 |
2017-03-31 |
$-13 |
2016-12-31 |
$-14 |
2016-09-30 |
$-12 |
2016-06-30 |
$-12 |
2016-03-31 |
$-10 |
2015-12-31 |
$-10 |
2015-09-30 |
$-9 |
2015-06-30 |
$-6 |
2015-03-31 |
$-7 |
2014-12-31 |
$-5 |
2014-09-30 |
$-3 |
2014-06-30 |
$-3 |
2014-03-31 |
$-1 |
2013-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.030B |
$0.050B |
Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a long-acting echinocandin antifungal, CD101 topical and C001 which are in different clinical trial. The company developed its product using Cloudbreak(TM) immunotherapy platform. Cidara Therapeutics, Inc. is headquartered in San Diego, California.
|